Fragment-based hit identification

thinking in 3D

Andrew D. Morley (Lead / Corresponding author), Angelo Pugliese, Kristian Birchall, Justin Bower, Paul Brennan, Nathan Brown, Tim Chapman, Martin Drysdale, Ian H. Gilbert, Swen Hoelder, Allan Jordan, Steven V. Ley, Andy Merritt, David Miller, Martin E. Swarbrick, Paul G. Wyatt (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    68 Citations (Scopus)

    Abstract

    The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.
    Original languageEnglish
    Pages (from-to)1221-1227
    Number of pages7
    JournalDrug Discovery Today
    Volume18
    Issue number23-24
    DOIs
    Publication statusPublished - Dec 2013

    Fingerprint

    Drug Industry
    Drug Discovery
    Libraries
    Pharmaceutical Preparations
    carbosulfan

    Cite this

    Morley, A. D., Pugliese, A., Birchall, K., Bower, J., Brennan, P., Brown, N., ... Wyatt, P. G. (2013). Fragment-based hit identification: thinking in 3D. Drug Discovery Today, 18(23-24), 1221-1227. https://doi.org/10.1016/j.drudis.2013.07.011
    Morley, Andrew D. ; Pugliese, Angelo ; Birchall, Kristian ; Bower, Justin ; Brennan, Paul ; Brown, Nathan ; Chapman, Tim ; Drysdale, Martin ; Gilbert, Ian H. ; Hoelder, Swen ; Jordan, Allan ; Ley, Steven V. ; Merritt, Andy ; Miller, David ; Swarbrick, Martin E. ; Wyatt, Paul G. / Fragment-based hit identification : thinking in 3D. In: Drug Discovery Today. 2013 ; Vol. 18, No. 23-24. pp. 1221-1227.
    @article{f99f514a6bc740729ecc25697dfd4d5e,
    title = "Fragment-based hit identification: thinking in 3D",
    abstract = "The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.",
    author = "Morley, {Andrew D.} and Angelo Pugliese and Kristian Birchall and Justin Bower and Paul Brennan and Nathan Brown and Tim Chapman and Martin Drysdale and Gilbert, {Ian H.} and Swen Hoelder and Allan Jordan and Ley, {Steven V.} and Andy Merritt and David Miller and Swarbrick, {Martin E.} and Wyatt, {Paul G.}",
    note = "Copyright {\circledC} 2013 Elsevier Ltd. All rights reserved.",
    year = "2013",
    month = "12",
    doi = "10.1016/j.drudis.2013.07.011",
    language = "English",
    volume = "18",
    pages = "1221--1227",
    journal = "Drug Discovery Today",
    issn = "1359-6446",
    publisher = "Elsevier",
    number = "23-24",

    }

    Morley, AD, Pugliese, A, Birchall, K, Bower, J, Brennan, P, Brown, N, Chapman, T, Drysdale, M, Gilbert, IH, Hoelder, S, Jordan, A, Ley, SV, Merritt, A, Miller, D, Swarbrick, ME & Wyatt, PG 2013, 'Fragment-based hit identification: thinking in 3D', Drug Discovery Today, vol. 18, no. 23-24, pp. 1221-1227. https://doi.org/10.1016/j.drudis.2013.07.011

    Fragment-based hit identification : thinking in 3D. / Morley, Andrew D. (Lead / Corresponding author); Pugliese, Angelo; Birchall, Kristian; Bower, Justin; Brennan, Paul; Brown, Nathan; Chapman, Tim; Drysdale, Martin; Gilbert, Ian H.; Hoelder, Swen; Jordan, Allan; Ley, Steven V.; Merritt, Andy; Miller, David; Swarbrick, Martin E.; Wyatt, Paul G. (Lead / Corresponding author).

    In: Drug Discovery Today, Vol. 18, No. 23-24, 12.2013, p. 1221-1227.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Fragment-based hit identification

    T2 - thinking in 3D

    AU - Morley, Andrew D.

    AU - Pugliese, Angelo

    AU - Birchall, Kristian

    AU - Bower, Justin

    AU - Brennan, Paul

    AU - Brown, Nathan

    AU - Chapman, Tim

    AU - Drysdale, Martin

    AU - Gilbert, Ian H.

    AU - Hoelder, Swen

    AU - Jordan, Allan

    AU - Ley, Steven V.

    AU - Merritt, Andy

    AU - Miller, David

    AU - Swarbrick, Martin E.

    AU - Wyatt, Paul G.

    N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.

    PY - 2013/12

    Y1 - 2013/12

    N2 - The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

    AB - The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.

    U2 - 10.1016/j.drudis.2013.07.011

    DO - 10.1016/j.drudis.2013.07.011

    M3 - Article

    VL - 18

    SP - 1221

    EP - 1227

    JO - Drug Discovery Today

    JF - Drug Discovery Today

    SN - 1359-6446

    IS - 23-24

    ER -

    Morley AD, Pugliese A, Birchall K, Bower J, Brennan P, Brown N et al. Fragment-based hit identification: thinking in 3D. Drug Discovery Today. 2013 Dec;18(23-24):1221-1227. https://doi.org/10.1016/j.drudis.2013.07.011